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Severity of renal vascular disease predicts mortality in patients Renal artery stenosis (RAS) is emerging as a common
undergoing coronary angiography. and frequently unsuspected cause of chronic renal failure
Background. Renal artery stenosis (RAS) is a relatively un- and end-stage renal disease (ESRD) [1, 2]. The vast major-common but potentially reversible cause of renal failure. In a
ity of cases in the expanding older population are dueprevious report, we demonstrated that the presence of RAS
to atherosclerotic disease, usually in the presence of wide-is independently associated with mortality in a group of patients
undergoing coronary angiography. Our current study expands spread disease affecting the coronary vessels, cerebrovas-
on this cohort, investigating the effect of the severity of RAS culature, and/or the vessels supplying the lower limbs [3, 4].
on all-cause mortality. In recent years, abdominal aortography at the time ofMethods. A total of 3987 patients underwent abdominal aor-
coronary angiography has been used to study the preva-tography immediately following coronary angiography. For the
lence of RAS [5]. Using this technique, incidental RASpurpose of survival analysis, significant RAS was defined as
75% narrowing in the luminal diameter. has been discovered in 15 to 20% of patients. In patient
Results. Significant RAS was present in 4.8% of patients groups undergoing aortography at the time of lower limb
studied and was bilateral in 0.8%. Factors associated with the
angiography, the prevalence has been reported as 14 topresence of RAS included female gender, older age, hyperten-
35% [6]. Progression in the severity of luminal narrowingsion, congestive heart failure, elevated serum creatinine, and
congestive heart failure. The four-year unadjusted survivals for is known to occur in 9 to 16% of cases, this being more
patients with and without significant RAS were 57 and 89%, likely to occur when the stenosis is 75% [7]. The pro-
respectively (P  0.001). Using the Cox proportional hazards portion of patients with ESRD attributable to atheroscle-model, the factors independently associated with decreased
rotic RAS has been reported as between 5 and 15%, asurvival were the presence of RAS, increased age, the severity
number that has risen substantially in recent years [8].of coronary artery disease, the presence of comorbid disease,
reduced ejection fraction, symptoms of congestive cardiac fail- We have previously studied the prevalence of RAS
ure, and the mode of treatment of coronary artery disease. In using an abdominal aortogram at the time of coronary
the multivariate model, the presence of RAS conferred a haz-
angiography, with RAS being defined as a 50% or greaterard ratio of 2.01 (95% CI, 1.51 to 2.67, P  0.001). We demon-
luminal narrowing [5, 9]. Our previous studies have de-strated an incremental effect on mortality according to the
severity of RAS at baseline. Four-year adjusted survival for fined the presence of RAS as a luminal narrowing of
patients with 50%, 75%, and 95% stenosis was 70%, 68%, 50% or greater on abdominal aortography. We have now
and 48%, respectively. In addition, bilateral disease was associ- extended these observations to include a larger patient
ated with four-year survival of 47% as compared with 59% for
population and employed the more rigorous definitionpatients with unilateral disease (P  0.001). The impact of
of RAS of 75% luminal narrowing on aortography. InRAS on survival remained robust regardless of the manner of
treatment of coronary artery disease [that is, medical, percuta- addition, patients were stratified as to their treatment of
neous transluminal coronary angioplasty (PTCA), or coronary coronary artery disease (CAD).
artery bypass graft (CABG)].
Conclusions. In this patient population, the presence of RAS
is a strong independent predictor of mortality. Increasing severity METHODS
of RAS has an incremental effect on survival probability.
Patient population
Over the course of 78 months, 7758 patients underwentKey words: renovascular disease, death, CABG, coronary angiography,
CAD, arterial stenosis, end-stage renal disease, chronic renal failure. elective diagnostic cardiac catheterization. Of these, 3987
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a database before the catheterization was performed. thereafter. Patients who did not respond were contacted
by telephone by trained interviewers. Data were re-Peripheral vascular disease was defined as a history of
corded regarding survival status, the development of car-claudication, previous vascular procedure, and/or physi-
diac events and admission to hospital.cal examination evidence of femoral or abdominal bruit.
Cerebrovascular disease was defined as a history of stroke
Statistical analysisor transient ischemic attack and/or carotid bruit on exam-
All categorical factors are described as number andination. Congestive heart failure symptoms were classified
percentage of patients with the factor. All continuousaccording to the New York Heart Association criteria.
measures are described with median as the measure ofHypercholesterolemia and hypertension were respec-
central tendency, with 25th and 75th percentiles includedtively defined as a total cholesterol of 5.5 mmol/L and
for measures of variability.diastolic BP 90 mm Hg or the use of antihypertensive
Comparisons of binary factors with the occurrence ofmedications before catheterization.
a renal arteriogram and with the presence of significant
RAS were made using likelihood ratio chi-square statis-Angiographic methods
tics. For categorical and continuous factors, Wilcoxon
Coronary angiography was performed via the femoral rank-sum tests were used.
artery approach using the Judkins technique. Coronary Cox proportional hazards regression modeling tech-
artery lesions graded as 75% luminal narrowing were niques were used in evaluating the prognostic signifi-
classified as significant. For the purposes of survival anal- cance of the factors of interest. A long-term clinical and
ysis, the severity of CAD was graded according to the catheterization survival model developed previously by
CAD Prognostic Index. After left ventriculography, the Mark et al used similar inclusion criteria [10]. The vari-
pigtail catheter was withdrawn into the abdominal aorta ables from that model were used as covariates in the
and positioned a few centimeters caudal to the renal arter- adjusted survival models.
ies. Aortography was performed in the anterior–posterior As has been shown previously, the adjusted mortality
projection with nonionic contrast, power-injected at a rate is worse initially with coronary artery bypass graft
of 20 mL/min to a total of 30 to 40 mL. The injection was (CABG) from the procedural deaths [11]. However, for
recorded on cine film at 30 frames per second. the patients who survive the procedure, adjusted mortal-
ity is better for CABG patients. As we were interested
Aortographic analysis in the effect of RAS on long-term survival, patients were
considered to be in the CABG or percutaneous translu-Aortograms were reviewed by a single observer who
minal coronary angioplasty (PTCA) treatment arms ifwas blinded to the clinical information. Narrowing of
the therapeutic procedure was performed within 30 daysthe luminal diameter of a major renal artery was quanti-
of catheterization. If they received both within the firstfied as 25%, 25 to 49%, 50 to 74%, 75 to 94%, 95 to
30 days, they were assigned to the treatment that they99%, and 100% and as bilateral or unilateral. Because
received first. If neither was used within the first 30of the difficulty in assessing minor degrees of arterial
days, they were assigned to the medically treated arm.narrowing, patients with normal renal arteries or any
Initiation into the study began 30 days after the time ofdegree of luminal narrowing50 were included with the
the procedure for the CABG and PTCA arms. It began50% group. For survival purposes, RAS was consid-
30 days after catheterization for the medical arm. In thisered significant if there was 75% luminal narrowing.
way, all early “in-hospital” deaths were equally excludedAccessory renal arteries were classified as major if it was
for all three arms.estimated that they supplied more than one third of the
Univariable analyses of RAS, bilateral renal disease,renal mass. Lesion location was defined as ostial, main
and creatinine levels were performed first. RAS, creati-artery (2 cm beyond the ostial segment), or branch
nine levels, and the interactions of RAS with treatment,vessel (beyond the first bifurcation of the renal artery).
CAD disease, and creatinine were added to the pre-
Patients were considered to have bilateral disease if they viously developed clinical and catheterization model us-
had 75% luminal narrowing in both renal arteries. Ste- ing Cox proportional hazards techniques. Backward vari-
notic lesions were designated as athereosclerotic if they able selection techniques were used to determine which
did not manifest the distinctive “string-of-beads” appear- of the additional renal variables and interactions added
ance characteristic of fibromuscular hyperplasia. No prognostically significant information.
complications related to the aortogram were observed. The unadjusted survival for the RAS subgroups are
illustrated using Kaplan-Meier survival curves. In the
Follow-up adjusted plots, survival estimates are calculated for the
All patients were followed prospectively using the average patient in this study using the clinical and cathe-
Duke Databank for Cardiovascular Disease for a median terization model plus renal stenosis, creatinine, and the
of 3.2 years. Follow-up information was collected using interactions of renal stenosis with procedural treatment
and CAD disease.mailed questionnaires six months, one year, and annually
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Table 1. Baseline characteristics of the patient population according Patient survival
to whether or not they underwent aortographic screening for renal
artery stenosis (RAS) The unadjusted survival probability, according to the
presence or absence of75% RAS, is depicted in FigureRenal arteriogram
1. The four-year survival of patients with and without
No Yes P value
significant RAS was 57 and 89%, respectively. The vari-N (N3771) (N3987) (N7758)
ables found to be associated with increased mortality
Male 7758 65 (2462) 69 (2752) 0.001
in the previously developed Cox proportional hazardsAge 7758 51/61/69 52/61/69 0.685
Canadian Heart class model [10] as well as the significant renal factors are
0 5289 13 (355) 12 (308) 0.001 summarized in Table 6. The interactions of RAS and of
1 1 (33) 2 (50)
serum creatinine with procedural treatment of CAD2 10 (274) 26 (643)
3 17 (470) 15 (367) were not statistically significant. Thus, the effects of RAS
4 41 (1170) 32 (784) and creatinine on outcome were not found to have
5 18 (521) 13 (314)
changed according to the mode of treatment of CAD orSmoker 7758 67 (2523) 67 (2675) 0.860
Hypertension 7758 55 (2076) 58 (2296) 0.024 the severity of disease.
Hyperlipidemia 7758 49 (1864) 52 (2074) 0.023 The presence of significant RAS, increased age, the
History of MI 7758 46 (1733) 53 (2111) 0.001
severity of CAD, the presence of co-morbid disease,CHF 7737 13 (473) 14 (568) 0.029
CHF (NYHA) reduced ejection fraction, symptoms of congestive car-
0 7733 88 (3306) 87 (3440) 0.057 diac failure, and the mode of treatment of coronary dis-
1 1 (23) 1 (37)
ease were all independently associated with reduced sur-2 2 (92) 3 (122)
3 3 (112) 3 (119) vival in this study. Gender and mitral regurgitation were
4 3 (104) 2 (99) no longer statistically significant (P  0.504 and P 
5 3 (120) 4 (159)
0.785, respectively) in the multivariate model. The find-Serum creatinine mg/L 4708 0.9 /1.1 /1.3 0.9 / 1.0 /1.2 0.001
ing of increased mortality in the presence of significantValues are given as % (number) and median with 25th, 75th percentiles.
Abbreviations are: MI, myocardial infarction; CHF, chronic heart failure; RAS remained robust regardless of whether CAD was
NYHA, New York Heart Association. treated medically, with PTCA or CABG (Figs. 2 and 3).
In the multivariate model, RAS conferred a hazard ratio
for death of 2.01 (95% CI, 1.51 to 2.67, P  0.001).
There was an incremental effect on mortality withRESULTS
respect to the severity of RAS. Four-year survival in
There were several significant differences in the base- patients with 50 to 75%, 75 to 95%, and 95% was
line variables (Tables 1 and 2) between those patients 70%, 68%, and 48%, respectively (Fig. 4). Patients with
who underwent aortography (N  3987) and those who significant unilateral RAS had a four-year survival of
did not (N  3771). Patients were less likely to undergo 59%, while those with significant bilateral disease had a
an aortogram if they had severe anginal symptoms, a low four-year survival probability of 47% (Fig. 5).
ejection fraction, raised serum creatinine, or a history of
congestive heart failure. On the other hand, patients
DISCUSSION
were more likely to undergo aortography if advanced
This study of a large cohort of patients undergoingcoronary disease was found at the time of coronary angi-
abdominal aortography at the time of coronary angiogra-ography.
phy provides a number of observations. First, we haveOne hundred ninety-one (4.8%) of the patients with
confirmed the frequent association of significant RASrenal arteriograms had renal artery luminal narrowing
with patients with underlying coronary disease. Second,of 75% (Table 3). Bilateral disease was present in
we demonstrated that the presence of asymptomatic
33 patients (0.8%). Patients with renal stenosis were at
RAS is associated with a profound effect on long-term
higher risk of cardiovascular disease than were those survival, regardless of the method of treatment of coro-
with less significant or no renal stenosis (Tables 4 and nary disease.
5). These patients were more often female, older, more This study notes a number of important differences
hypertensive, more likely to have chronic heart failure from our previous studies (although the current study
(CHF), had higher serum creatinine, and more extensive includes patients from our earlier work [5], they are in
coronary disease. Percutaneous coronary interventions addition many more in this cohort) in which RAS was
were more prevalent in the patients with 75% than defined as 50% or greater luminal narrowing. In particu-
those with 75% renal stenosis (37% vs. 19%). CABG lar, these earlier reports did not demonstrate an associa-
and no interventional therapy occurred more often in tion between 50% luminal narrowing and the presence
those with increased renal stenosis (39% vs. 31% and of hypertension. Using the more stringent definition of
75% luminal narrowing, hypertension is strongly associ-41% vs. 32%, respectively).
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Table 2. Severity of coronary artery disease (CAD) according to whether or not the patient underwent aortographic screening for
renal artery stenosis (RAS)
Renal angiogram
No Yes P value
N (N3771) (N3987) (N7758)
Number of vessels 7758
1 VD 61 (2288) 43 (1711) 0.001
2 VD 27 (1013) 30 (1183)
3 VD 12 (470) 27 (1093)
LAD disease (75%): Yes 6442 79 (1954) 68 (2716) 0.001
CAD index 7758
1 VD 75% 12 (448) 11 (426) 0.001
1 VD 95% 42 (1580) 28 (1097)
2 VD 14 (535) 10 (405)
2 VD, 2 severe 2 (92) 5 (180)
1 VD, 95% proximal LAD, or 2 VD, 95% LAD 14 (534) 16 (632)
2 VD, 95% proximal LAD, or 3 VD 3 (128) 4 (174)
3 VD, 1 severe 8 (317) 18 (728)
3 VD, 75% proximal LAD 2 (60) 4 (152)
3 VD, 95% proximal LAD 2 (77) 5 (193)
Ejection fraction % 5220 38/49/60 46/56/64 0.001
Values are expressed as % (number) and median with 25th and 75th percentiles. Abbreviations are: VD, vessel disease; LAD, left anterior descending artery.
Table 4. Baseline characteristics of the patient population accordingTable 3. Breakdown of patient numbers according to
severity of renal artery stenosis (RAS) (N3987) to the presence or absence of significant renal artery stenosis (RAS)
Renal stenosisProportion of all patients
Degree of stenosis No. of patients undergoing aortography
75% 75% P value
N (N3796) (N191) (N3987)50% 3625 90.9%
50–75% 171 4.3%
Male 3987 70 (2662) 47 (90) 0.00175–95% 99 2.5%
Age 3987 51/60/69 63/70/76 0.00195–99% 75 1.9%
Canadian Heart class 2466Total occlusion 17 0.4%
0 12 (288) 16 (20) 0.095
Bilateral disease 33 0.8% 1 2 (50) 0 (0)
2 27 (623) 16 (20)
3 15 (345) 17 (22)
4 32 (743) 33 (41)
5 12 (291) 18 (23)
Smoker 3987 67 (2547) 67 (128) 0.981ated and probably reflects the greater hemodynamic sig-
Hypertension 3987 57 (2150) 76 (146) 0.001nificance of 75% luminal narrowing. We also controlled
Hyperlipidemia 3987 52 (1984) 47 (90) 0.165
for the mode of treatment of CAD, a factor that has History of MI 3987 53 (2019) 48 (92) 0.175
CHF 3978 13 (500) 36 (68) 0.001a large impact on overall mortality. Additionally, our
CHF (NYHA) 3976current study found that increasing the severity of RAS 0 88 (3314) 66 (126) 0.001
was independently associated with an incremental in- 1 1 (34) 2 (3)
2 3 (112) 5 (10)crease in all-cause mortality. Survival after four years
3 3 (100) 10 (19)varied from 48% in patients with 95% luminal nar- 4 2 (86) 7 (13)
rowing up to 90% in patients with no RAS on abdominal 5 4 (139) 10 (20)
Serum creatinine mg/L 3304 0.9/1.0/1.2 1.0/1.2/1.5 0.001aortography. On the whole, significant RAS, defined as
Values are given as % (number) or median with 25th, 75th percentiles. Abbre-75% narrowing, was associated with a four-year sur-
viations are: MI, myocardial infarction; CHF, chronic heart failure; NYHA, New
vival rate of 57%. Our study was not designed to examine York Heart Association.
the association between RAS and the development of
ESRD, as it was not included on the data set.
onary disease was present. These factors may have af-Our study was performed on a select group of patients
fected the prevalence of RAS, although they tend towho were undergoing coronary angiography and there-
push the prevalence in opposing directions so the netfore deemed to be at high risk for atherosclerotic disease.
effect was likely to be small.Consequently, the results may not be generally applica-
These findings are consistent with previous studies,ble to other patient groups. In addition, the likelihood
virtually all of which have found RAS to be an indepen-of undergoing aortography at the time of coronary angi-
dent marker of increased mortality. In a precursor toography was lower in the presence of a raised serum
creatinine or severe angina, and higher when severe cor- the present study, it was found that four-year all-cause
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Table 5. Severity of coronary artery disease (CAD) according to the presence or absence of significant renal artery stenosis (RAS)
Renal stenosis
75% 75% P value
N (N3796) (N191) (N3987)
Number of vessels 3987
1 VD 44 (1661) 26 (50) 0.001
2 VD 29 (1119) 34 (64)
3 VD 27 (1016) 40 (77)
LAD disease (75%): Yes 3969 68 (2568) 78 (148) 0.015
CAD index 3987
1 VD 75% 11 (413) 7 (13) 0.001
1 VD 95% 28 (1064) 17 (33)
2 VD 10 (382) 12 (23)
2 VD, 2 severe 5 (176) 2 (4)
1 VD, 95% proximal LAD, or 2 VD, 95% LAD 16 (595) 19 (37)
2 VD, 95% proximal LAD, or 3 VD 4 (170) 2 (4)
3 VD, 1 severe 18 (680) 25 (48)
3 VD,  5% proximal LAD 4 (137) 8 (15)
3 VD, 95% proximal LAD 5 (179) 7 (14)
Ejection fraction % 3941 46/56/64 39/52/65 0.116
Values are expressed as % (number) or median with 25th and 75th percentiles. Abbreviations are: VD, vessel disease; LAD, left anterior descending artery.
Fig. 1. Kaplan-Meier survival curve showing
unadjusted survival according to the presence
or absence of significant renal artery stenosis
(RAS; P  0.001). Symbols are: (thick line)
75% RAS; (thin line) 75% RAS.
mortality in those with 50% luminal narrowing was
67% compared with 88% in those without it [9]. Our
Table 6. Effect of clinical- and catheterization-derived variables on findings confirm and expand on those results. They dem-mortality as assessed by the Cox proportional hazards model
onstrate that the strong association of RAS and in-
Hazard ratio creased mortality remain robust regardless of the methodVariable (95% CI) P value
of coronary revasularization. The finding of a consistent
CAD index (63 vs. 32) 2.54 (1.68–3.85) 0.001
incremental increase in mortality with increasing severity75% RAS 2.01 (1.51–2.67) 0.001
Age (69 years vs. 52 years) 1.99 (1.69–2.34) 0.001 of RAS strengthens the case for a true biological rela-
Treatment of CAD (CABG vs. medical) 0.54 (0.39–0.74) 0.001 tionship. In addition, patients with ESRF due to ischemicTreatment of CAD (PTCA vs. medical) 0.61 (0.48–0.78) 0.001
nephropathy have a very high mortality rate. One studyEjection fraction (64% vs. 46%) 0.73 (0.64–0.83) 0.001
Presence of co-morbid illness (yes vs. no) 1.34 (1.21–1.47) 0.001 by Mailloux et al found a five-year survival rate of 18%,
Serum creatinine (1.2 vs. 0.9) mg/L 1.24 (1.14–1.34) 0.001
with a median survival after commencing dialysis of 25CHF (V vs. 0) 1.57 (1.18–2.09) 0.002
Mitral regurgitation (yes vs. no) 1.10 (0.82–1.48) 0.504 months [12]. This prognosis is among the worst of all
Gender (male vs. female) 1.03 (0.84–1.25) 0.785 patient groups presenting with ESRF.
Abbreviations are: CAD, coronary artery disease; RAS, renal artery stenosis; Valentine et al demonstrated that asymptomatic RAS
CABG, coronoary artery bypass graft; PTCA, petcutaneous transliminal coro-
nary angioplasty. was a stronger predictor of mortality following abdomi-
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Fig. 2. Adjusted survival according to the
presence or absence of significant renal artery
stenosis (RAS) in patients treated with percuta-
neous transluminal angioplasty (PTCA) (P 
0.001). Symbols are: (thick line) 75% RAS;
(thin line) 75% RAS.
Fig. 3. Adjusted survival according to the
presence or absence of significant renal artery
stenosis (RAS) in patients treated with coro-
nary artery bypass graft (CABG) (P 0.001).
Symbols are: (thick line) 75% RAS; (thin
line) 75% RAS.
nal aortic surgery than clinically overt CAD [4]. In their male gender [9]. The ischemic kidney is known to pro-
duce increased amounts of renin, with consequent angio-and other similar studies, death most frequently was due
to cardiovascular or cerebrovascular disease rather than tensin II production [17]. The latter is a potent vasocon-
strictor and has been implicated in the activation of cellrenal failure [13, 14]. In addition, studies of percutaneous
or surgical revascularization of ischemic kidneys have proliferation systems [18]. High levels of angiotensin II
are associated with accelerated atherogenesis [19] andlargely failed to show a clinically significant improvement
in blood pressure or survival benefit [15, 16]. Conse- left ventricular hypertrophy [20]. This model is certainly
too simplistic to explain fully the excess mortality inquently, there has been much debate as to the nature of
the link between atherosclerotic RAS and mortality, a patients with RAS although it does provide a conceptual
starting point from which to address the question.link that appears to be as strong as that for CAD. It
is probable that unsuspected atherosclerotic RAS is a From a practical point of view it seems attractive to
attempt revascularization of these ischemic kidneys. Asmarker for aggressive atherogenesis in many vascular
beds. This increased risk appears to be independent of mentioned, however, the outcomes in most studies look-
ing at this have been unimpressive with respect to bothtraditional markers of progressive atherosclerosis, such
as hyperlipidemia, hypertension, diabetes mellitus, and improvement in blood pressure and prevention of pro-
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Fig. 4. Adjusted survival stratified for the se-
verity of renal artery stenosis (RAS) (P 
0.001 for trend). Symbols are: (thick line) 10
to 75% RAS; (medium line) 75 to 95% RAS;
(thin line) 95% RAS.
Fig. 5. Adjusted survival according to the
presence of unilateral (thick line) or bilateral
(thin line) renal artery stenosis (RAS) (P 
0.001).
gressive renal failure [21]. However, despite the lack of ACKNOWLEDGMENTS
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